SLRN: ACELYRIN Company Aggregate Debts

Acelyrin, Inc. (SLRN) relies on a solid liquidity reserve to develop treatments for inflammatory pathologies. Its scientific potential is based on the development of antibodies for ophthalmology and immunology, including isobotolimab. The share price visualized below, where the individual debt metric is 0.00, accompanies a period of preparation for Phase 2/3 publications. Growth is expected from test results and new partnerships regarding isobelibag.

Acelyrin, Inc. - SLRN Company Debts (period 02/21/2024 - 05/31/2025)

Analytical breakdowns and data insights for company ACELYRIN (SLRN)

- price and consensus price forecast:
Price Performance Chart ACELYRIN Inc.|SLRN - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization ACELYRIN, Inc.|SLRN - Total Company Value
- book capitalization data:
Accounting Value of a Share ACELYRIN|SLRN - Company Book Value|Market Cap to Net Assets Ratio acelyrin.com|SLRN - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Acelyrin, Inc.|SLRN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Acelyrin Inc.|SLRN - Company Debts|Debts to Book Value ACELYRIN, Inc.
Fundamental company valuation:SLRN (ACELYRIN Inc.)

This indicator synthesizes daily market data for the continuous monitoring of total liabilities, allowing investors to assess liquidity risk and debt service costs outside of quarterly reports. For Acelyrin, Inc. (SLRN), changes in debt load reflect the balance between funding costly immunological research and maintaining the financial stability necessary to implement long-term option programs for retaining key scientists.

Analysis of competing companies

Aggregate Debt Obligations Haleon Corp (HLN)|Company Aggregate Debts KVUE (Kenvue Inc.)|veronapharma.com - Company Aggregate Debts|Company Debts Jyong Biotech (MENS)|LGND: Aggregate Debt Obligations|AMRX (Amneal Pharmaceuticals Inc) - Company Debts|Perrigo Corp (PRGO) - Company Total Debt|ALVO (Alvotech) - Company Aggregate Debts|Company Aggregate Debts liquidia.com (LQDA)|Galapagos (GLPG) - Company Total Debt|Aggregate Debt Obligations ANIP (ANI Pharmaceuticals Inc)|MNKD: Company Debts|AMPH - Company Cumulative Debt|Company Total Debt Pacira BioSciences PCRX|SPRY - Company Cumulative Indebtedness|Company Aggregate Debts Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Aggregate Debt Obligations|Company Aggregate Debts SCPH (scPharmaceuticals, Inc.)|Company Cumulative Debt TECX|Tonix Pharmaceuticals (TNXP) - Company Debts|Aggregate Debt Obligations sxtchina.com (SXTC)|Company Aggregate Debts EPRX (Eupraxia Pharmaceuticals Inc.)|Company Aggregate Debts BioHarvest Sciences, Inc. BHST|EXOZ: Company Aggregate Debts|ORMP - Company Total Debt|Company Aggregate Debts ENTX|HYFT (ipatherapeutics.com) - Company Cumulative Debt|Company Debts ABVC BioPharma, Inc.|Company Debts Cumberland Pharmaceuticals Inc (CPIX)|Quantum BioPharma Limited - Company Total Debt|Company Cumulative Debt FGEN (FibroGen Corporation)|Company Debts Telomir Pharmaceuticals|Aggregate Debt Obligations Rani Therapeutics Holdings RANI|Company Aggregate Debts SNYR (Synergy CHC Corporation)|RLYB: Company Total Debt Obligations|Company Debts lexariabioscience.com|Company Aggregate Debt Pulmatrix Corporation|PTHL - Company Total Debt|Aggregate Debt Obligations Aptorum|LYRA (Lyra Therapeutics) - Company Aggregate Debts|Company Total Debt Obligations IBO (Impact BioMedical, Inc.)|TNFA - Company Debts|Company Aggregate Debt cbdMD Inc. YCBD|PRFX: Company Aggregate Debts|Altamira Therapeutics (CYTO) - Company Total Debt|Lipella Pharmaceuticals, Inc. - Company Total Debt|OPTN (OptiNose Inc) - Company Total Debt Obligations|PIRS: Company Debts|Company Total Debt Obligations PROC|Company Debts Petros Pharmaceuticals (PTPI)|Company Debts QLI (qlsyy.net)|Company Debts TFF Pharmaceuticals, Inc.